Maria Letícia de Castro Barbosa

Prof. Maria Letícia de Castro Barbosa

Department of Pharmaceutical Sciences, Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
Lidia Moreira LimaLidia Moreira Lima
Lidia Moreira Lima
RTRoberta Tesch
Roberta Tesch
CSCarlos Mauricio R. Sant'Anna
Carlos Mauricio R. Sant'Anna
FTFrank Totzke
Frank Totzke
EBEliezer J Barreiro
Eliezer J Barreiro

1 July 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YSYolanda Karla Cupertino da Silva
Yolanda Karla Cupertino da Silva
CACristina Villarinho Augusto
Cristina Villarinho Augusto
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
GMGabriela Muniz de Albuquerque Melo
Gabriela Muniz de Albuquerque Melo
AQAline Cavalcanti de Queiroz
Aline Cavalcanti de Queiroz
MAMagna Suzana Alexandre-Moreira
Magna Suzana Alexandre-Moreira

7 April 2017 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
RCRaissa Alves da Conceicao
Raissa Alves da Conceicao
AFAline Guerra Manssour Fraga
Aline Guerra Manssour Fraga
BCBarbara Dias Camarinha
Barbara Dias Camarinha
GSGabriela Cristina de Carvalho Silva
Gabriela Cristina de Carvalho Silva
VLViviane de Oliveira Freitas Lione
Viviane de Oliveira Freitas Lione
Cancer incidence represents an important public health problem worldwide. Nuclear factor kappa B (NF-κB) transcription factor plays a pivotal role in the regulation of genes that control various responses in eukaryotic cells, including proliferation and survival, cytoskeletal remodeling, cellular adhesion and apoptosis. Extensive studies have demonstrated the contribution of NF-κB transcription in the promotion and progression of several hematological malignancies and solid tumors, in which NF-κB constitutive activation and/or overexpression are common clinical features. Moreover, triggering NF-κB pathway is already considered one important mechanism of resistance development to chemotherapy and radiotherapy, indicating that the inhibition of this signaling cascade is a promising approach to enhance efficacy and prevent acquired resistance in cancer treatment. In this review, research efforts dedicated to the identification of novel NF-κB signaling pathway inhibitors as promising anticancer drug candidates are described.

6 June 2018 in MedChemComm
Verified
Journal Article
Closed access
PDF file
PSPaula Nogueira da Silva
Paula Nogueira da Silva
RCRaissa Alves da Conceição
Raissa Alves da Conceição
RMRodolfo Do Couto Maia
Rodolfo Do Couto Maia
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
Novel SGLT-2 selective inhibitors, an innovative therapeutic approach for glycemia control in diabetic patients.

4 March 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
GMGabriela Muniz de Albuquerque Melo
Gabriela Muniz de Albuquerque Melo
YSYolanda Karla Cupertino da Silva
Yolanda Karla Cupertino da Silva
RLRaquel de Oliveira Lopes
Raquel de Oliveira Lopes
ESEverton Tenório de Souza
Everton Tenório de Souza
Lidia Moreira LimaLidia Moreira Lima
Lidia Moreira Lima

1 September 2011 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
MFMilla Machado Fumian
Milla Machado Fumian
AMAna Luísa Palhares de Miranda
Ana Luísa Palhares de Miranda
EBEliezer J Barreiro
Eliezer J Barreiro
Lidia Moreira LimaLidia Moreira Lima
Lidia Moreira Lima
Tumor necrosis factor (TNF) consists of an inflammatory cytokine essential for homeostasis and organism defense. Despite its physiological relevance, both increased biosynthesis and release of TNF lead to the exacerbation of inflammatory and oxidative responses, which are related to the pathogenesis of a host of diseases of an inflammatory, autoimmune and/or infectious nature. In this context, effective therapeutic approaches for the modulation of TNF have been the focus of research efforts. Approximately one million individuals worldwide have been treated with biotechnological inhibitors of this cytokine, the so-called anti-TNF biopharmaceuticals. However, given the high risk of infection and the limitations related to cost and administration routes, new therapeutic approaches aimed at biological targets that directly or indirectly modulate the production and/or activation of TNF appear promising alternatives for the discovery of new anti-inflammatory and immunomodulatory orally active drugs and are therefore discussed in this paper.